KRTX Company Profile and Key Details
Karuna Therapeutics, Inc.
KRTX Stock Price Chart
Stock Price Today
Karuna Therapeutics, Inc. (KRTX) stock surged +0.03%, trading at $329.83 on NASDAQ, up from the previous close of $329.74. The stock opened at $329.75, fluctuating between $329.75 and $329.97 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Company Information
| Employees | 339 |
| Beta | 1.15 |
| Sales or Revenue | $654.00K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Karuna Therapeutics, Inc. (NASDAQ: KRTX) stock price is $329.83 in the last trading session. During the trading session, KRTX stock reached the peak price of $329.97 while $329.75 was the lowest point it dropped to. The percentage change in KRTX stock occurred in the recent session was 0.03% while the dollar amount for the price change in KRTX stock was $0.09.
The NASDAQ listed KRTX is part of Biotechnology industry that operates in the broader Healthcare sector. Karuna Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Troy A. Ignelzi
Chief Financial Officer & Sec.
Mr. Jason Parker Brown
Chief Financial Officer
Dr. Steven M. Paul M.D.
Pres of R&D, Chief Scientific Officer & Director
Ms. Charmaine Lykins
Chief Commercial Officer
Mr. Jonathan Rosin
Chief HR Officer
Dr. Stephen K. Brannan
Chief Medical Officer
Dr. Ronald N. Marcus M.D.
Senior Vice President of Medical
Mr. William Meury
Pres, Chief Executive Officer & Director
Mr. William P. Kane Jr.
Chief Commercial Officer
Ms. Mia Kelley J.D.
Vice President of Legal Affairs
Dr. Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisor
Ms. Stephanie Moore
Vice President of HR
Dr. Andrew Craig Miller
Co-Founder & Chief Operating Officer
KRTX's closing price is 108.26% higher than its 52-week low of $158.38 where as its distance from 52-week high of $329.99 is -0.05%.
Number of KRTX employees currently stands at 339.
Official Website of KRTX is: https://www.karunatx.com
KRTX could be contacted at phone 857 449 2244 and can also be accessed through its website. KRTX operates from 99 High Street, Boston, MA 02110, United States.
KRTX stock volume for the day was 1.28M shares. The average number of KRTX shares traded daily for last 3 months was 971.83K.
The market value of KRTX currently stands at $12.60B with its latest stock price at $329.83 and 38.2M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com